Compare RBCAA & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBCAA | ADMA |
|---|---|---|
| Founded | 1974 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 1998 | 2012 |
| Metric | RBCAA | ADMA |
|---|---|---|
| Price | $96.46 | $9.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 97.7K | ★ 2.4M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | 0.35 |
| Revenue | ★ $417,495,000.00 | $42,219,783.00 |
| Revenue This Year | $3.93 | $27.46 |
| Revenue Next Year | N/A | $22.11 |
| P/E Ratio | $125.66 | ★ $26.69 |
| Revenue Growth | 8.50 | ★ 43.85 |
| 52 Week Low | $63.97 | $7.21 |
| 52 Week High | $102.22 | $20.46 |
| Indicator | RBCAA | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 56.46 |
| Support Level | $88.24 | $8.20 |
| Resistance Level | $102.11 | $10.35 |
| Average True Range (ATR) | 2.26 | 0.35 |
| MACD | -0.68 | 0.01 |
| Stochastic Oscillator | 23.11 | 57.25 |
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking, which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending, and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans, and receipt and payment of federal.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.